Aug 16 (Reuters) - CSL Ltd CSL.AX
* Co's FY18 NPAT "expected to be in the range of about $1,480 million to $1,550 million at constant currency"
* In first half FY18, CSL intends to approach us private placement market to raise approximately US$600 million for general corporate purposes
* "No share buyback is foreshadowed in FY18"
* "Expect solid ongoing demand for CSL Behring Biotherapies and strong market acceptance of our newly approved specialty product Haegarda"
* "Seqirus is expected to continue its path toward profitability"